Streptozotocin mechanisms and its role in rodent models for Alzheimer’s disease

The majority of dementia is caused by Alzheimer’s disease (AD) that manifests in the familial and sporadic forms. The latter accounts for the most of the cases and is a complex multi-factorial disorder with no cure. Despite the vast growth of animal models, both the transgenic and non-transgenic the...

全面介绍

书目详细资料
发表在:Toxin Reviews
主要作者: 2-s2.0-85144019319
格式: Review
语言:English
出版: Taylor and Francis Ltd. 2023
在线阅读:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144019319&doi=10.1080%2f15569543.2022.2150646&partnerID=40&md5=c8c7cef3b13813327fab53557bf2226b
实物特征
总结:The majority of dementia is caused by Alzheimer’s disease (AD) that manifests in the familial and sporadic forms. The latter accounts for the most of the cases and is a complex multi-factorial disorder with no cure. Despite the vast growth of animal models, both the transgenic and non-transgenic therapeutic findings for AD seem ambiguous. Streptozotocin (STZ) administration is the most accepted sporadic rodent AD model due to its ability to mimic the sporadic variety in humans. Current literature lacks the information on the underlying mechanism of STZ with the formation of the neuropathological hallmarks of AD. Thus, this study focused on developing a comprehensive review on the mechanism of STZ in inducing diabetogenic effects, insulin signaling dysfunction, neuroinflammation, oxidative stress, cerebral amyloid angiopathy, and cholinergic deficit in AD rodent models. Also, we discussed the considerations that should be made when designing the AD rodent model. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
ISSN:15569543
DOI:10.1080/15569543.2022.2150646